Carrie L Lucas

List of Publications by Year
in descending order

39 papers	2,923 citations	361045 20 h-index	414034 32 g-index
49 all docs	49 docs citations	49 times ranked	4447 citing authors

#	Article	IF	Citations
1	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110Î´ result in T cell senescence and human immunodeficiency. Nature Immunology, 2014, 15, 88-97.	7.0	575
2	Mg ²⁺ Regulates Cytotoxic Functions of NK and CD8 T Cells in Chronic EBV Infection Through NKG2D. Science, 2013, 341, 186-191.	6.0	269
3	PI3KÎ´ and primary immunodeficiencies. Nature Reviews Immunology, 2016, 16, 702-714.	10.6	259
4	Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. Journal of Experimental Medicine, 2014, 211, 2537-2547.	4.2	249
5	Effective â€œactivated PI3KÎ´ syndromeâ€â€“targeted therapy with the PI3KÎ´ inhibitor leniolisib. Blood, 2017, 130, 2307-2316.	0.6	227
6	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase Î´ syndrome 2: AÂcohort study. Journal of Allergy and Clinical Immunology, 2016, 138, 210-218.e9.	1.5	215
7	A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell, 2020, 181, 1194-1199.	13.5	185
8	Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity, 2021, 54, 1083-1095.e7.	6.6	164
9	SARS-CoV-2â€“related MIS-C: A key to the viral and genetic causes of Kawasaki disease?. Journal of Experimental Medicine, 2021, 218, .	4.2	100
10	Conformational disruption of PI3KÎ´ regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1982-1987.	3.3	92
11	Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nature Medicine, 2022, 28, 879-882.	15.2	72
12	Novel PIK3CD mutations affecting N-terminal residues of p110Î´ cause activated PI3KÎ´ syndrome (APDS) in humans. Journal of Allergy and Clinical Immunology, 2017, 140, 1152-1156.e10.	1.5	62
13	Human PI3KÎ³ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nature Communications, 2019, 10, 4364.	5.8	51
14	Genomics of Immune Diseases and New Therapies. Annual Review of Immunology, 2016, 34, 121-149.	9.5	47
15	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	2.0	43
16	A CD8 T cellâ€“intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. Blood, 2010, 115, 1280-1287.	0.6	40
17	LAG-3, TGF-Î², and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. Blood, 2011, 117, 5532-5540.	0.6	38
18	Epsteinâ€“Barr Virus Susceptibility in Activated PI3KÎ´ Syndrome (APDS) Immunodeficiency. Frontiers in Immunology, 2017, 8, 2005.	2.2	33

#	Article	IF	Citations
19	Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation. Nature Immunology, 2021, 22, 1118-1126.	7.0	30
20	The Mystery of MIS-C Post-SARS-CoV-2 Infection. Trends in Microbiology, 2020, 28, 956-958.	3.5	26
21	Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. Journal of Translational Medicine, 2011, 9, 203.	1.8	22
22	The role of PI3KÎ³ in the immune system: new insights and translational implications. Nature Reviews Immunology, 2022, 22, 687-700.	10.6	22
23	Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. Haematologica, 2020, 105, e488.	1.7	17
24	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. PLoS ONE, 2020, 15, e0236921.	1.1	13
25	Novel compound heterozygous variants in NHLRC2 in a patient with FINCA syndrome. Journal of Human Genetics, 2020, 65, 911-915.	1.1	11
26	Infections in activated PI3K delta syndrome (APDS). Current Opinion in Immunology, 2021, 72, 146-157.	2.4	11
27	Identifying genetic determinants of autoimmunity and immune dysregulation. Current Opinion in Immunology, 2015, 37, 28-33.	2.4	10
28	Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2). Journal of Clinical Immunology, 2021, 41, 680-683.	2.0	7
29	Expression and purification of soluble murine CD40L monomers and polymers in yeast Pichia pastoris. Protein Expression and Purification, 2011, 76, 115-120.	0.6	6
30	Editorial: Human Disorders of PI3K Biology. Frontiers in Immunology, 2020, 11, 617464.	2.2	3
31	Layers of regulation in induction of mixed chimerism by anti-CD40L. Chimerism, 2011, 2, 111-113.	0.7	2
32	Maximizing insights from monogenic immune disorders. Current Opinion in Immunology, 2021, 73, 50-57.	2.4	2
33	Molecular Basis of Cell Death Programs in Mature T Cell Homeostasis. , 2014, , 41-59.		0
34	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. , 2020, 15, e0236921.		0
35	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. , 2020, 15, e0236921.		0
36	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. , 2020, 15, e0236921.		0

#	Article	IF	Citations
37	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. , 2020, 15, e0236921.		0
38	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. , 2020, 15, e0236921.		0
39	The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. , 2020, 15, e0236921.		0